非小细胞肺癌表皮生长因子受体基因19、21外显子突变情况及其与患者临床病理特征、吉非替尼治疗后疗效相关性探讨

Study on the Relationship between the Mutation 19 21exon of Non-small Cell Lung Cancer Epidermal Growth Factor Receptor Gene and Its Clinicopathological Features and the Efficacy of Gefitinib Treatment

目的:探讨非小细胞肺癌表皮生长因子受体基因19、21外显子突变情况及其与患者临床病理特征、吉非替尼治疗后疗效相关性。方法:选取2015年1月~2015年3月到某院接受治疗的60例患者作为研究对象,所有患者入院后经过各项详细检测以及组织病理学部门诊断确实为非小细胞肺癌。采用直接测序法检测60例患者的表皮生长因子受体基因19、21外显子突变情况。结果:男性和女性患者有统计学意义(P<0.05);腺癌与鳞癌两种突变率有统计学意义(P<0.05);吸烟患者和不吸烟患者两者突变率有统计学意义(P<0.05)。结论:EGFR基因突变状态与患者的性别、病理类型以及是否吸烟有关,EGFR基因突变状态到目前还不能作为化疗疗效以及远期生存的预测因子。

Objective：To investigate the Relationship between the mutation 19 21 exon of non-small cell lung cancer epidermal growth gactor receptor gene and its clinicopathological features and the efficacy of Gefitinib treatment.Methods：60 cases of patients treated in the hospital from January 2015 to March 2015 were selected as the research object,and all patients admitted to the hospital after the detailed inspection and pathology department were diagnosed non-small cell lung cancer.Direct sequencing method was used to detect the mutations of epidermal growth factor receptor gene 19 and exon 21 in 60 patients.Results：The results were statistically significant in both male and female patients（P〈0.05）;adenocarcinoma and squamous cell carcinoma in two kinds of mutation rate was statistically significant（P〈0.05）;two patients with smoking and nonsmoking patients with mutation rate was statistically significant（P〈0.05）.Conclusion：EGFR gene mutation status with gender,pathological type and whether smoking,EGFR gene mutation status to is still not as chemotherapy efficacy and predictors of long-term survival.